Connection

ELIZABETH SHPALL to Drug Administration Schedule

This is a "connection" page, showing publications ELIZABETH SHPALL has written about Drug Administration Schedule.
  1. Vorinostat Combined with High-Dose Gemcitabine, Busulfan, and Melphalan with Autologous Stem Cell Transplantation in Patients with Refractory Lymphomas. Biol Blood Marrow Transplant. 2015 Nov; 21(11):1914-20.
    View in: PubMed
    Score: 0.020
  2. Future strategies for the treatment of advanced epithelial ovarian cancer using high-dose chemotherapy and autologous bone marrow support. Gynecol Oncol. 1994 Sep; 54(3):357-61.
    View in: PubMed
    Score: 0.019
  3. Evaluation of bendamustine in combination with fludarabine in primary chronic lymphocytic leukemia cells. Blood. 2014 Jun 12; 123(24):3780-9.
    View in: PubMed
    Score: 0.019
  4. Autologous stem cell transplantation for refractory or poor-risk relapsed Hodgkin's lymphoma: effect of the specific high-dose chemotherapy regimen on outcome. Biol Blood Marrow Transplant. 2013 Mar; 19(3):410-7.
    View in: PubMed
    Score: 0.017
  5. High-dose infusional gemcitabine combined with busulfan and melphalan with autologous stem-cell transplantation in patients with refractory lymphoid malignancies. Biol Blood Marrow Transplant. 2012 Nov; 18(11):1677-86.
    View in: PubMed
    Score: 0.017
  6. Prophylaxis of graft-versus-host disease in unrelated donor transplantation with pentostatin, tacrolimus, and mini-methotrexate: a phase I/II controlled, adaptively randomized study. J Clin Oncol. 2011 Jan 20; 29(3):294-302.
    View in: PubMed
    Score: 0.015
  7. Clofarabine ? fludarabine with once daily i.v. busulfan as pretransplant conditioning therapy for advanced myeloid leukemia and MDS. Biol Blood Marrow Transplant. 2011 Jun; 17(6):893-900.
    View in: PubMed
    Score: 0.015
  8. Low-dose azacitidine after allogeneic stem cell transplantation for acute leukemia. Cancer. 2009 May 01; 115(9):1899-905.
    View in: PubMed
    Score: 0.013
  9. Once daily i.v. busulfan and fludarabine (i.v. Bu-Flu) compares favorably with i.v. busulfan and cyclophosphamide (i.v. BuCy2) as pretransplant conditioning therapy in AML/MDS. Biol Blood Marrow Transplant. 2008 Jun; 14(6):672-84.
    View in: PubMed
    Score: 0.013
  10. Pharmacokinetics of once-daily IV busulfan as part of pretransplantation preparative regimens: a comparison with an every 6-hour dosing schedule. Biol Blood Marrow Transplant. 2007 Jan; 13(1):56-64.
    View in: PubMed
    Score: 0.011
  11. Fixed-dose single agent pegfilgrastim for peripheral blood progenitor cell mobilisation in patients with multiple myeloma. Br J Haematol. 2006 Jun; 133(5):533-7.
    View in: PubMed
    Score: 0.011
  12. Safeguarding the administration of high-dose chemotherapy: a national practice survey by the American Society for Blood and Marrow Transplantation. Biol Blood Marrow Transplant. 1997 Dec; 3(6):331-40.
    View in: PubMed
    Score: 0.006
  13. Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgrastim in breast cancer patients. Blood. 1997 Oct 15; 90(8):2939-51.
    View in: PubMed
    Score: 0.006
  14. Paclitaxel-containing high-dose chemotherapy: the University of Colorado experience. Semin Oncol. 1996 Dec; 23(6 Suppl 15):43-8.
    View in: PubMed
    Score: 0.006
  15. The Duke AFM Program. Intensive induction chemotherapy for metastatic breast cancer. Cancer. 1990 Aug 01; 66(3):431-6.
    View in: PubMed
    Score: 0.004
  16. High-dose combination alkylating agents with bone marrow support as initial treatment for metastatic breast cancer. J Clin Oncol. 1988 Sep; 6(9):1368-76.
    View in: PubMed
    Score: 0.003
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.